Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
675 stopped studies mapped to Digestive System Adenocarcinoma and descendants · 93% state a reason
Over the 675 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00459108 | Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by… | Phase 2 | terminated | Apr 11, 2007 | National Cancer Institute (NCI) | Halted early for futility. | Efficacy / futility |
| NCT02149771 | Combination Treatment for Advanced Liver Cancer | Phase 3 | withdrawn | May 29, 2014 | Shanghai Zhongshan Hospital | Insufficient funding | Funding |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal… | Phase 2 | terminated | Dec 23, 2015 | Criterium, Inc. | Lack of Enrollment | Enrollment / accrual |
| NCT01359007 | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer | Phase 2 | terminated | May 24, 2011 | University of Oklahoma | The principal investigator terminated the study due to inactivity and low enrollment | Investigator |
| NCT01710293 | Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in…(PACT CREATE 3) | N/A | withdrawn | Oct 19, 2012 | VA Office of Research and Development | Unable to obtain data needed to run the RCT; project never began recruitment | Enrollment / accrual |
| NCT02110953 | Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal… | Phase 1 | terminated | Apr 10, 2014 | Fox Chase Cancer Center | IRB study closure by investigator due to low enrollment | Investigator |
| NCT02496832 | A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With… | N/A | withdrawn | Jul 14, 2015 | University Health Network, Toronto | Study was never initiated | Other (stated, no rule matched) |
| NCT00878215 | Clinical Application of Image-Guided Liver Surgery | Phase 2 | terminated | Apr 8, 2009 | Washington University School of Medicine | The image-guidance system became commercially available | Other (stated, no rule matched) |
| NCT02392377 | Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal… | Phase 2 | terminated | Mar 19, 2015 | Case Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT01934179 | Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal… | — | terminated | Sep 4, 2013 | Fox Chase Cancer Center | Low Accrual Rate | Enrollment / accrual |
| NCT01956864 | Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer | Phase 1 | withdrawn | Oct 8, 2013 | Johns Hopkins University | PI transferred from Georgetown to Johns Hopkins University. No participants enrolled at either… | Enrollment / accrual |
| NCT02407561 | Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein… | — | terminated | Apr 3, 2015 | Castle Biosciences Incorporated | Futility - unable to secure sites and samples for participation | Efficacy / futility |
| NCT02908165 | Randomized Phase II Trial of Chemoembolization and Sorafenib | Phase 2 | withdrawn | Sep 20, 2016 | Yale University | A future study will be taking place using the same patient population. | Other (stated, no rule matched) |
| NCT00848783 | Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed… | Phase 2 | terminated | Feb 20, 2009 | NYU Langone Health | Due to slow accrual | Enrollment / accrual |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | Phase 1 | terminated | Nov 13, 2009 | Masonic Cancer Center, University of Minnesota | PI left institution. | Investigator |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced…(ARTEMIS-Eso) | Phase 1 / Phase 2 | withdrawn | Oct 12, 2017 | Jules Bordet Institute | Suspended collaboration with the company providing the study drug | Sponsor / business decision |
| NCT02406508 | Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib… | Phase 2 | withdrawn | Apr 2, 2015 | Delcath Systems Inc. | No enrollment in the study | Enrollment / accrual |
| NCT02549755 | 11C-acetate for Treatment Response After Radiotherapy for HCC | Phase 2 | terminated | Sep 15, 2015 | Justin Sims | Poor enrollment | Enrollment / accrual |
| NCT00003530 | Antineoplaston Therapy in Treating Patients With Primary Liver Cancer | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT02958163 | Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)(HepSTAR) | Phase 2 | terminated | Nov 8, 2016 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | lack of recruitment | Enrollment / accrual |
| NCT01606124 | Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer | Phase 2 | terminated | May 25, 2012 | Mayo Clinic | pending expiration of the supply of study agent. | Drug supply |
| NCT02026362 | Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients…(HCC DC CTL) | Phase 1 / Phase 2 | suspended | Jan 3, 2014 | HRYZ Biotech Co. | Interim analysis | Efficacy / futility |
| NCT02585687 | Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the…(ETAFIRM) | N/A | terminated | Oct 23, 2015 | Hospices Civils de Lyon | problems with enrollment | Enrollment / accrual |
| NCT01489410 | Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma | N/A | withdrawn | Dec 9, 2011 | University of Minnesota | Insufficient staff | Other (stated, no rule matched) |
| NCT01668017 | A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein… | Phase 1 | terminated | Aug 17, 2012 | Merck KGaA, Darmstadt, Germany | The sponsor decided not to conduct the expansion part of trial (part 2) | Sponsor / business decision |
| NCT02821533 | Chemoembolization for Hepatocellular Carcinoma | Phase 2 | terminated | Jul 1, 2016 | Chinese University of Hong Kong | Poor case accrual | Enrollment / accrual |
| NCT01191385 | GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar… | — | withdrawn | Aug 30, 2010 | Bayer | Study is officially cancelled bevore FPFV. | Other (stated, no rule matched) |
| NCT02959359 | DAA in the Risk of Recurrence After Curative Treatment of HCC | Phase 4 | withdrawn | Nov 9, 2016 | Taipei Veterans General Hospital, Taiwan | The supplies of study drug were halted by Gilead Sciences Ltd. | Other (stated, no rule matched) |
| NCT01114256 | FNA Tumor Sampling for CD137 Modulation: A Pilot Study | — | terminated | May 3, 2010 | Stanford University | not stated | Not stated |
| NCT00085410 | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic… | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | The trial was discontinued early due to no confirmed partial responses. | Other (stated, no rule matched) |
| NCT00787787 | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic… | Phase 2 | terminated | Nov 10, 2008 | University of Washington | not stated | Not stated |
| NCT02202759 | A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction | Phase 2 | terminated | Jul 29, 2014 | Millennium Pharmaceuticals, Inc. | Business Decision, No Safety or Efficacy Concerns | Safety / toxicity |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | Phase 2 | terminated | Jul 29, 2014 | Millennium Pharmaceuticals, Inc. | Business Decision, No Safety or Efficacy Concerns | Safety / toxicity |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | Phase 1 / Phase 2 | terminated | Jul 29, 2009 | Massachusetts General Hospital | Funding was withdrawn after only 10 participants were enrolled | Enrollment / accrual |
| NCT01005875 | Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma(RAD 0901) | N/A | terminated | Nov 2, 2009 | University of Alabama at Birmingham | Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is… | Enrollment / accrual |
| NCT01942083 | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to… | Phase 1 | terminated | Sep 13, 2013 | Korea Otsuka Pharmaceutical Co., Ltd. | Company decision | Sponsor / business decision |
| NCT02856867 | Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric…(MEGAN) | Phase 2 | withdrawn | Aug 5, 2016 | European Organisation for Research and Treatment of Cancer - EORTC | not stated | Not stated |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | Phase 2 | terminated | Jun 23, 2011 | Novartis Pharmaceuticals | The study was terminated due to low enrollment. This resulted in the study being underpowered and… | Enrollment / accrual |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced… | Phase 1 / Phase 2 | withdrawn | Aug 28, 2014 | Amgen | Study stopped due to administrative reasons | Other (stated, no rule matched) |
| NCT00455091 | A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma | — | terminated | Apr 3, 2007 | National Health Research Institutes, Taiwan | No cases enrollment | Enrollment / accrual |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular… | Phase 2 | terminated | Jul 28, 2010 | Seoul National University Hospital | There were problems with national reimbursement policies. | Other (stated, no rule matched) |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing… | Phase 1 / Phase 2 | withdrawn | Dec 20, 2016 | University of Michigan Rogel Cancer Center | funding issues | Funding |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT01849588 | HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) | Phase 4 | terminated | May 8, 2013 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT02819869 | The Combination Effect of Statin Plus Metformin on Relapse-free | Phase 2 | terminated | Jun 30, 2016 | Taipei Medical University WanFang Hospital | insufficient for the fund | Funding |
| NCT03117855 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct… | Phase 1 | withdrawn | Apr 18, 2017 | City of Hope Medical Center | Company no longer interested in supporting this trial | Sponsor / business decision |
| NCT02413853 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients…(PRIMIER) | Phase 2 | withdrawn | Apr 10, 2015 | University of Southern California | Study drug supply issues | Drug supply |
| NCT03026803 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | Phase 2 | terminated | Jan 20, 2017 | City of Hope Medical Center | Due to Sorafenib became first line treatment for HCC, the designed treatment became less… | Sponsor / business decision |
| NCT03113604 | Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in…(SLAMF3) | — | withdrawn | Apr 13, 2017 | Centre Hospitalier Universitaire, Amiens | The study has been stopped because no one is | Other (stated, no rule matched) |
| NCT01270438 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients… | Phase 2 | withdrawn | Jan 5, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 19, 2018source: clinicaltrials